This is an aggregated industry headline. Read the full story at PharmaVoice →
Corvus CEO thinks his next blockbuster is an ITK inhibitor
It's like "Rituxan all over again," said CEO Richard Miller who believes Corvus' lead candidate could make an impact in both cancer and autoimmune diseases.
By PharmaVoice
· Jun 16, 2026
· via PharmaVoice
Image: PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…
The WeekFierceBiotech ↗
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was…
The WeekBriefing
Novartis’ Pluvicto won FDA approval on July 31 for use with ARPI therapy in PSMA-positive metastatic androgen …